GUTS SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Fractyl (GUTS) Investors of Securities Class Action Lawsuit Deadline on October 20, 2026

Faruqi & Faruqi is investigating potential securities claims against Fractyl Health related to investors who acquired securities from January 13, 2025, through January 29, 2026. A federal securities class action has been filed against the company, and the deadline to seek lead-plaintiff status is October 20, 2026.

Analysis

This is a procedural litigation update, not evidence that the allegations have been established or that Fractyl’s operating outlook has changed. The October 20 lead-plaintiff deadline may keep GUTS in the news and add near-term volatility, but the notice supplies no allegations, claimed loss mechanism, or independently verified financial impact. The key market transmission is therefore sentiment and risk-premium—not a quantifiable earnings revision. Over the next 1–3 months, the complaint’s specific claims, any company response, and whether additional plaintiffs or investigations emerge matter more than the deadline itself. Over 6–18 months, exposure depends on case progression, potential settlement or defense costs, insurance, and any underlying disclosure or operating issues; none can be assessed from this notice. A contrarian read is that a law-firm solicitation can sound more consequential than the procedural step warrants. Conversely, if the underlying complaint identifies a material disclosure failure or creates financing/capital-markets friction, the current notice may understate the longer-lived overhang. No valuation or price target is supportable without the complaint, share-price reaction, cash runway, and relevant company disclosures.

Key Decisions for Investors

• Do not initiate a directional GUTS trade solely on this solicitation. Treat the October 20 deadline as a short-lived headline catalyst, not a merits finding.
• Review the filed complaint and any company response for the alleged statements, corrective disclosure dates, and claimed link to investor losses; these are necessary to judge whether the case changes the fundamental thesis.
• Monitor GUTS trading, financing disclosures, and cash runway for evidence that litigation is affecting liquidity or access to capital. Escalate to a negative-risk view only if those indicators or the underlying allegations support it.
• Falsification of a sustained litigation-overhang thesis: no material new allegations or company disclosures, no financing or operating deterioration, and GUTS stabilizing after the procedural deadline. A materially adverse complaint or related disclosure would invalidate that benign view.